MX2015006289A - Composiciones y metodos para la modulacion de la expresion del receptor del factor de crecimiento de fibroblastos tipo 3 (fgfr3). - Google Patents
Composiciones y metodos para la modulacion de la expresion del receptor del factor de crecimiento de fibroblastos tipo 3 (fgfr3).Info
- Publication number
- MX2015006289A MX2015006289A MX2015006289A MX2015006289A MX2015006289A MX 2015006289 A MX2015006289 A MX 2015006289A MX 2015006289 A MX2015006289 A MX 2015006289A MX 2015006289 A MX2015006289 A MX 2015006289A MX 2015006289 A MX2015006289 A MX 2015006289A
- Authority
- MX
- Mexico
- Prior art keywords
- fgfr3
- modulation
- compositions
- methods
- fgfr3 expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261729922P | 2012-11-26 | 2012-11-26 | |
| PCT/EP2013/074552 WO2014080004A1 (en) | 2012-11-26 | 2013-11-25 | Compositions and methods for modulation of fgfr3 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006289A true MX2015006289A (es) | 2015-12-03 |
Family
ID=49639882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006289A MX2015006289A (es) | 2012-11-26 | 2013-11-25 | Composiciones y metodos para la modulacion de la expresion del receptor del factor de crecimiento de fibroblastos tipo 3 (fgfr3). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9725723B2 (enExample) |
| EP (1) | EP2922955B1 (enExample) |
| JP (1) | JP6463687B2 (enExample) |
| KR (1) | KR20150088305A (enExample) |
| CN (1) | CN104903448B (enExample) |
| BR (1) | BR112015012051A2 (enExample) |
| CA (1) | CA2889993A1 (enExample) |
| DK (1) | DK2922955T3 (enExample) |
| MX (1) | MX2015006289A (enExample) |
| RU (1) | RU2015120645A (enExample) |
| WO (1) | WO2014080004A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
| WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
| JP6126009B2 (ja) | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | α−シヌクレイン発現の調節 |
| EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| CN104661664B (zh) | 2012-07-13 | 2020-07-03 | 波涛生命科学有限公司 | 手性控制 |
| AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| JP6463687B2 (ja) | 2012-11-26 | 2019-02-06 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | Ｆｇｆｒ３の発現の調節のための組成物及び方法 |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| CN113278617A (zh) | 2014-01-16 | 2021-08-20 | 波涛生命科学有限公司 | 手性设计 |
| KR102793563B1 (ko) | 2016-03-04 | 2025-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| FI3769765T3 (fi) | 2018-03-19 | 2024-05-15 | Taiho Pharmaceutical Co Ltd | Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus |
| JP7762071B2 (ja) * | 2020-01-31 | 2025-10-29 | 国立大学法人京都大学 | 軟骨形成異常症の治療 |
| WO2022211095A1 (ja) * | 2021-03-31 | 2022-10-06 | ルクサナバイオテク株式会社 | Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| KR100782896B1 (ko) | 1999-05-04 | 2007-12-06 | 엑시콘 에이/에스 | Ｌ-리보-ｌｎａ 유사체 |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| JP4731324B2 (ja) | 2003-08-28 | 2011-07-20 | 武 今西 | Ｎ−ｏ結合性架橋構造型新規人工核酸 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2007061130A1 (ja) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | 多発性骨髄腫に対する抗腫瘍剤 |
| US7399845B2 (en) | 2006-01-27 | 2008-07-15 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| JP5731115B2 (ja) | 2006-05-05 | 2015-06-10 | アイシス ファーマシューティカルズ， インコーポレーテッド | 遺伝子発現を調節するための化合物および方法 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| MX2009002856A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Conjugados polimericos que contienen porciones cargadas positivamente. |
| AU2007296054B2 (en) | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| ATE538127T1 (de) | 2007-07-05 | 2012-01-15 | Isis Pharmaceuticals Inc | 6-disubstituierte bicyclische nukleinsäureanaloga |
| WO2009090182A1 (en) * | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| DK3702371T5 (da) * | 2009-03-25 | 2024-08-26 | Genentech Inc | Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse |
| WO2011139843A2 (en) * | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| JP6463687B2 (ja) | 2012-11-26 | 2019-02-06 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | Ｆｇｆｒ３の発現の調節のための組成物及び方法 |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-11-25 JP JP2015543449A patent/JP6463687B2/ja not_active Expired - Fee Related
- 2013-11-25 CN CN201380061132.9A patent/CN104903448B/zh not_active Expired - Fee Related
- 2013-11-25 KR KR1020157016841A patent/KR20150088305A/ko not_active Withdrawn
- 2013-11-25 US US14/647,430 patent/US9725723B2/en not_active Expired - Fee Related
- 2013-11-25 DK DK13795243.8T patent/DK2922955T3/da active
- 2013-11-25 EP EP13795243.8A patent/EP2922955B1/en not_active Not-in-force
- 2013-11-25 CA CA2889993A patent/CA2889993A1/en not_active Abandoned
- 2013-11-25 MX MX2015006289A patent/MX2015006289A/es unknown
- 2013-11-25 WO PCT/EP2013/074552 patent/WO2014080004A1/en not_active Ceased
- 2013-11-25 BR BR112015012051A patent/BR112015012051A2/pt active Search and Examination
- 2013-11-25 RU RU2015120645A patent/RU2015120645A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014080004A1 (en) | 2014-05-30 |
| CN104903448B (zh) | 2017-07-11 |
| BR112015012051A2 (pt) | 2017-12-12 |
| EP2922955B1 (en) | 2019-03-06 |
| DK2922955T3 (da) | 2019-05-13 |
| JP2016501520A (ja) | 2016-01-21 |
| KR20150088305A (ko) | 2015-07-31 |
| RU2015120645A (ru) | 2017-01-10 |
| US9725723B2 (en) | 2017-08-08 |
| JP6463687B2 (ja) | 2019-02-06 |
| EP2922955A1 (en) | 2015-09-30 |
| CA2889993A1 (en) | 2014-05-30 |
| US20150307886A1 (en) | 2015-10-29 |
| HK1208702A1 (en) | 2016-03-11 |
| CN104903448A (zh) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015006289A (es) | Composiciones y metodos para la modulacion de la expresion del receptor del factor de crecimiento de fibroblastos tipo 3 (fgfr3). | |
| CA2871471C (en) | Dna-pk inhibitors | |
| IN2015DN01300A (enExample) | ||
| MX2014002990A (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf. | |
| WO2014028429A3 (en) | Enzymes and polymerases for the synthesis of rna | |
| MX2012003770A (es) | Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia. | |
| MY203474A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| MX344521B (es) | Aminas heterociclicas y sus usos. | |
| BR112014021612A2 (pt) | composições e métodos para modulação da expressão de atxn3 | |
| MX356625B (es) | Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva. | |
| WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| WO2013040436A3 (en) | Esx-mediated transcription modulators and related methods | |
| GB201021867D0 (en) | Non-coding immunomodulatory DNA construct | |
| WO2014060848A3 (en) | Treatment methods using adenovirus | |
| EA201301336A1 (ru) | Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии | |
| IN2015KN00492A (enExample) | ||
| WO2011021177A3 (en) | Compositions and methods for prognosis and treatment of prostate cancer | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| WO2011130426A3 (en) | Compositions and methods for treatment of melanoma | |
| WO2012138708A8 (en) | Mhc engagement and clip modulation for the treatment of disease | |
| MX2013015347A (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
| GB2507700A (en) | Compositions and methods for treatment of metastatic cancer | |
| WO2011103028A3 (en) | Compositions and methods for inhibiting mmset |